Kornimate/medical-research-clean huggingface dataset:
irbesartan effects on endothelial dysfunction in hypertensive type ii diabetic patients comparing atenolol

Conditions: Hypertension; Diabetes Mellitus Type 2

Summary: to show that irbesartan improves endothelial dysfunction and the procoagulant state which are thought to be the possible mechanisms, inducing a generalized vasculopathy associated with microalbuminuria and vascular events in type ii diabetic hypertensive patients


Eligibility criteria:
inclusion criteria: * non insulin dependent type ii manifest diabetes with glycosilated hba1c levels over %6.5-8 * mild to moderate hypertension stage i and stage ii according to esc-esh 2003 (140-180 mmhg) exclusion criteria: * congestive heart failure * azotemia * insulin dependent diabetes * liver insufficiency * pregnancy * cancer the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Keywords: microalbuminaria in hypertensive patients with type ii diabetes mellitus
dose responsiveness as a measure of clinical effectiveness during neuromonitored spine surgery

Conditions: Intervertebral Disc Degeneration; Intervertebral Disc Displacement; Spinal Curvatures; Spinal Stenosis; Spondylitis; Spondylosis

Summary: intraoperative neuromonitoring (ionm) is a tool used by neurophysiologists during spine surgery to prevent irreversible damage to the spinal cord during procedures through a system of alerts. this study investigates the effectiveness of ionm in 300 participants receiving spine surgery. the goal of this study is to refine the alert criteria for procedures in which ionm is used.

intraoperative neurophysiological monitoring (ionm) measures neural function and integrity during surgical procedures. through ionm, neurodiagnostic procedures can help determine whether any nerves have become compressed or if the brain or spinal cord has any reduced vascular flow, allowing the surgical team to take immediate and corrective actions to prevent a bad outcome. essentially, ionm acts as an early warning system for surgeons to gain reliable insight into a patient's condition during surgery, adding a layer of safety to the measures already in place that monitor cardiac and respiratory function while a patient is anesthetized. we propose an observational research study to enhance the evidence-base for ionm. a novel prospective neuromonitoring database will be implemented. in addition to the usual contingency data to assess prediction accuracy, other measures will be examined: 1. a "dose effect of injury" assessment. three categories of injury will be recorded by physicians: (a) no new deficit; (b) new minor deficit; and (c) new severe deficit. 2. the outcome effect of intraoperative test frequency will be evaluated (infrequent vs average vs very frequent), leading to a "dose effect of neuromonitoring" assessment. here we hypothesize that within our prospective sample, there is a relationship between the proportion of total new neurological deficits (new minor deficit + new severe deficit) and the frequency of ionm testing. more frequent testing is associated with fewer total new neurological deficits. 3. patient reported outcomes will be evaluated longitudinally in conjunction with clinical outcomes data. patient interviews will be conducted by a trained research assistant aided by department technologists. patient-reported neurological outcome assessments will be supplemented/confirmed by review of in- and outpatient surgical/neurophysiologist physician chart notes. data from this proposed observational study will allow real-life outcomes based improvement in the field of ionm.

Eligibility criteria:
inclusion criteria: * must be 18+ years old * patients must be undergoing cervical and/or thoracic spine surgical procedure at abbott northwestern hospital in minneapolis, mn exclusion criteria: * patients who are non-english speakers * patients with ongoing psychiatric concerns are excluded * patients unwilling to be contacted for a 6-month follow-up

Keywords: ionm
expanded access to tipifarnib

Conditions: HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)

Summary: requests for single patient expanded access to tipifarnib may be considered for adult patients with hras mutations or peripheral t cell lymphoma (ptcl). to request access, use responsible party contact information provided in this record. expanded access for tipifarnib is only available in the united states.


Eligibility criteria:
inclusion/exclusion criteria: diagnosed with hras-mutant carcinomas or peripheral t cell lymphoma (ptcl). adult, ages 18+. have exhausted appropriate standard treatments without success and no comparable or satisfactory alternative treatment is available or exists to treat the disease or condition. is ineligible for participation in any ongoing clinical study of the investigational drug, which includes lack of access due to geographic limitations. meets any other pertinent medical criteria for access to the investigational drug, as established by the kura oncology

Keywords: lymphoma t-cell peripheral non-hodgkin hras peripheral t-cell
a pilot study to assess the impact of exposure to popular media content on patients living with obesity

Conditions: Obesity

Summary: this study will explore the impact of exposure to popular media content on patients living with obesity. findings from this study will provide new insights that will extend current understanding of exposure to media portrayal. this is a proof of principle pilot study that will evaluate the feasibility of recruitment, randomisation, assessment procedures and implementation of the intervention with the aim to facilitate the planning and the conduct of a full-scale randomised controlled trial.

this study will explore the impact of exposure to popular media content on patients living with obesity. findings from this study will provide new insights that will extend current understanding of exposure to media portrayal. this is a proof of principle pilot study that will evaluate the feasibility of recruitment, randomisation, assessment procedures and implementation of the intervention with the aim to facilitate the planning and the conduct of a full-scale randomised controlled trial.

Eligibility criteria:
inclusion criteria: 1. female adults aged 18-65 years. 2. body mass index equal or greater than 30 kg/m2. 3. weight stable at time of recruitment, defined as less than 5% variation in body weight over the preceding 3 months. 4. proficient in written and spoken english. 5. able to comply with study protocol. 6. willing and able to provide written informed consent. exclusion criteria: 1. type 1 and type 2 diabetes (in view of altered circulated gut hormone profiles and gustatory function). 2. smoking (in view of the fact that smoking affects salivary cortisol). 3. diagnosed with uncontrolled severe depression. 4. diagnosed with uncontrolled psychiatric disorder. 5. previous bariatric surgery. 6. acute illness or chronic conditions that may impact hpa including cushing syndrome. 7. known or suspected history of hiv, hepatitis b or c or other blood-borne diseases (in view of safety regulations regarding exposure to blood products). 8. currently using glucocorticoids. 9. pregnancy or lactation. 10. elevated self-perceived stress as assessed by the perceived stress scale.

Keywords: obesity media content
neuromodulation and dynamic balance in stroke

Conditions: Stroke

Summary: portable neuromodulation stimulator (pons) is non-invasive stimulation device placed on the tongue to stimulate those brain regions understood to be important for maintaining balance. this research study aims to collect evidence that pons therapy along with balance training improves postural and walking stability post-stroke.


Eligibility criteria:
inclusion criteria: * at least six months since the onset of ischemic or hemorrhagic stroke. * demonstrate residual paresis in the lower extremity (fugl-mayer lower extremity score \< 34). * are able to provide informed consent demonstrated by their ability to weigh the consequences of participating versus not participating in the study. * can walk at least 10 feet with and without assistive device. * functional gait assessment score \<22. exclusion criteria: * pre-existing neurological disorders. * previous stroke affecting the other hemisphere . * severe arthritis or orthopedic problems that limit passive range of motion. * areas of recent bleeding or open wounds. * lack normal sensation on the tongue. * received treatment for cancer within the past year. * non-removable metal orthodontic devices. * oral health problems. * are sensitive to nickel, gold or copper. * chronic infectious diseases. * are pregnant. * have dementia
a longitudinal study of plasma ebv dna in nasopharyngeal carcinoma from both endemic and non-endemic patient populations

Conditions: Mouth Cancer; Lip Cancer; Throat Cancer; Lip Neoplasms; Head and Neck Cancers

Summary: 1. to determine the prognostic implication of plasma epstein-bar virus (ebv) dna concentrations, as measured by quantitative polymerase chain reaction (pcr) in patients with nasopharyngeal carcinoma (npc). 2. to relate pretreatment plasma ebv dna concentration to who classification of these tumors both in endemic and non-endemic areas. 3. to determine whether pretreatment plasma ebv dna can serve as a prognostic factor for both endemic and non-endemic patient populations.


Eligibility criteria:
inclusion criteria: * having a new diagnosis of nasopharyngeal carcinoma. * being treated with either radiotherapy or chemoradiotherapy for this condition. exclusion criteria: * age \<18 since npc is a very rare condition in this age group and may have a different biological behavior * patients who are unable to provide informed consents for themselves.
pemetrexed as first line chemotherapy for advanced breast cancer

Conditions: Breast Cancer

Summary: the purposes of this study are to determine the safety of pemetrexed and any side effects that might be associated with it, whether pemetrexed can help patients with breast cancer and how much pemetrexed should be given to patients.


Eligibility criteria:
inclusion criteria: * be at least 18 years of old. * have been diagnosed with breast cancer * at least one year disease-free interval after initial treatment. * have pre-study laboratory tests that are within the requirements of this study. * be able to visit the doctor's office weekly during the treatment period. exclusion criteria: * to be pregnant or breastfeeding. * to be currently taking aspirin or aspirin- like medicine and unable to stop for a few days during each cycle of therapy. * to have received prior chemotherapy for the treatment of metastatic cancer. patients may have received prior hormonal treatment. * to have another illness that your doctor thinks would make you unable to participate. * to be unable or not willing to take folic acid and vitamin b12.
travoprost new formulations in patients with open-angle glaucoma or ocular hypertension

Conditions: Ocular Hypertension; Open-angle Glaucoma

Summary: the purpose of this study was to describe the safety and iop-lowering efficacy of travoprost new formulations compared to travatan® and to vehicle in patients with open-angle glaucoma or ocular hypertension.


Eligibility criteria:
inclusion criteria: * satisfy all informed consent requirements; * diagnosed with open-angle glaucoma or ocular hypertension; * able to discontinue use of all iop-lowering medications for a minimum of 5 to 28 days prior to the eligibility 1 visit; * iop measurements in at least 1 eye as specified in protocol; * other protocol-specified inclusion criteria may apply. exclusion criteria: * females of childbearing potential if pregnant, breastfeeding, or not using highly effective birth control measures; * any form of glaucoma other than open-angle glaucoma; * severe central visual field loss in either eye; * chronic, recurrent or severe inflammatory eye disease; * clinically relevant or progressive retinal disease such as retinal degeneration, diabetic retinopathy, or retinal detachment, in the opinion of the investigator; * best-corrected visual acuity (bcva) worse than 0.60 logarithm of the miniminum angle of resolution (logmar); * intraocular surgery within the past 6 months; * ocular laser surgery within the past 3 months; * any abnormality preventing reliable applanation tonometry; * severe illness or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study; * other protocol-specified exclusion criteria may apply.

Keywords: iop open-angle glaucoma ocular hypertension
effect of bt and pfet on urinary symptoms and quality of life in patients with oabs

Conditions: Overactive Bladder Syndrome (OABS)

Summary: the aim of this study was to examine the effects of bladder training and pelvic floor exercise training programs given in addition to botulinum toxin-a (btx-a) application on urinary symptoms and quality of life in patients with overactive bladder syndrome (aams) who do not respond to conservative treatments. individuals who meet the criteria for inclusion in the study and agree to participate in the study will be divided into 2 separate research branches.the patients to be included in the study will be divided into two groups as "group 1=botox + physiotherapy " or "group 2=botox group ". in addition to the btx-a application, bladder training and pelvic floor exercise training will be applied to patients in the first group, while standard patient training will be provided to patients in the second group. severity of urinary symptoms, quality of life and subjective perception of improvement before btx-a application, 2 weeks and 12 weeks after btx-a application, international incontinence consultation questionnaire - women's lower urinary tract symptoms (iciq-fluts), 1-hour ped test, international incontinence consultation- lower urinary tract symptoms quality of life scale (iciq-luts) and global perception of improvement will be evaluated.


Eligibility criteria:
inclusion criteria: * over the age of 18 (those with a mini mental test score of 24 and above for individuals over the age of 65), * who has non-neurogenic overactive bladder syndrome, * patients who received routine botulinum toxin-a administration because they did not respond to conservative treatment, * patients who volunteer to participate in the study will be included. exclusion criteria: * patients with neurogenic overactive bladder syndrome, * pregnant women, * lack of cooperation in evaluation and/or treatment and lack of literacy status, * patients with urogynocological/anatomical abnormalities, * patients receiving pelvic radiation therapy, * patients with psychiatric or neurogenic disorders and * patients who have not given consent to the study and do not have an informed consent form (bgof).

Keywords: pelvic floor exercise bladder training standard patient education botulinum toxin-a btx-a
development of an screening system in children with congenital heart disease based on cloud computing and big data

Conditions: Heart Diseases

Summary: this study intends to establish an automatic system for screening on children with congenital heart disease, the system include the auscultation of cardiac murmur and the test of oxygen saturation, the data was analyzed based on the cloud computing.

this study intends to establish a system for screening of children with congenital heart disease,with the combination of cardiac auscultation , the test of oxygen saturation, the use of cloud computing and data base. the investigators decide to do this project from three main points.1:how to establish a data-base system? 2:how to get heart sound signal? 3.how to analyze so many signals?

Eligibility criteria:
inclusion criteria: * neonatal ward patients * patients with echocardiography reports exclusion criteria: * severe pneumonia

Keywords: fetal heart sounds big data cloud computing congenital heart disease data base acoustic structure design
a 3-year study following up patients with moderate to severe rheumatoid arthritis treated with humira in greece

Conditions: Rheumatoid Arthritis

Summary: the objectives of the study are to observe and assess the long-term use, safety and efficacy of humira (adalimumab), as prescribed by the rheumatologist in a normal clinical setting and in accordance with the terms of the european marketing authorization and to observe compliance of patients with the prescribed treatment.

this is a multi-center, uncontrolled observational study of patients who at the time of entry had moderate to severe rheumatoid arthritis (rα) and who were subsequently prescribed humira (adalimumab) following normal clinical practice, with or without other anti-rheumatic treatments, prior to enrollment in this study. once the physician has determined that the patient meets the inclusion criteria, and the patient has agreed to be included in the observational study by signing the informed consent, the patient's day 1 demographic data, and disease status will be reported in the day 1 data report forms. the physician will then follow-up with the patient via regular office visits at intervals as determined by routine clinical practice. patient's safety and efficacy data, if they are part of clinical routine, will be recorded in the data report forms at day 1, and regular visits which are closest to month 3, month 6, month 9, month 12, month 18, month 24, month 30, and month 36.

Eligibility criteria:
inclusion criteria: * patients with moderate or severe active rheumatoid arthritis, who have been prescribed and are receiving humira (adalimumab) under normal clinical practice for at least one month prior to inclusion and according to the approved summary of product characteristics (spc) in the european union. * patients must be willing to consent to data being collected and provided to abbott laboratories. exclusion criteria: * contraindications according to the spc. * patients should not participate in another observational abbott study.

Keywords: evaluation of safety and efficacy adalimumab treatment rheumatoid arthritis
study evaluating gemtuzumab ozogamicin in acute myelogenous leukemia after stem cell transplant

Conditions: Acute Myelogenous Leukemia

Summary: the primary objective of this study is to evaluate the safety of gemtuzumab ozogamicin in relapsed cd33-positive aml patients who received hsct. if the mtd dose is not reached, 9 mg/m2 will be the maximum tested dose. a secondary objective is to assess efficacy in terms of the number of patients attaining a complete (cr) or morphological (crp) remission.


Eligibility criteria:
inclusion criteria * patients with cd33+ aml who have experienced relapse after autologous or allogeneic hsct. flow cytometry, performed at the study site, must demonstrate that the patient has aml that is cd33 positive, based on local laboratory criteria (patients with history of mds pretransplant will be eligible if their proportion of myeloblasts by marrow aspirate exceeds 5% at time of evaluation for gemtuzumab ozogamicin treatment) * the patient must be greater than or equal to 60 days post-hcst * patients of all ages may be entered in this study exclusion criteria * peripheral white blood count (wbc) greater than or equal to 30,000/ul at the time of initial gemtuzumab ozogamicin administration. (in order to reduce the peripheral blood count, patients may be treated with hydroxyurea. hydroxyurea must be discontinued 24 hours prior to gemtuzumab ozogamicin administration.) * known active central nervous system (cns) or testicular leukemia at time of study entry. * prior therapy with anti-cd33 antibodies.

Keywords: leukemia stem cell transplant
an intervention for primary caregivers to improve outcomes in children with severe malnutrition

Conditions: Child Malnutrition

Summary: this cluster-randomized controlled trial will evaluate the effectiveness of a four-day hospital-based intervention program for primary caregivers of children with severe malnutrition.

mortality rates remain high in hospitalized children with severe malnutrition and long-term impairments in child development exist in children that do survive. hospitalized children with severe malnutrition will be allocated to an intervention or standard of care group in each one-week cycle. the intervention package consists of a counseling and support program that includes three modules: 1) psychosocial stimulation; 2) nutrition and feeding; and 3) water, sanitation and hygiene. assessments will be done at baseline (t=0) and follow-up (t=6 months). the primary outcome is child development, which will be assessed using the malawi developmental assessment tool, a validated tool for gross and fine motor, language, and social development.

Eligibility criteria:
inclusion criteria: * child 6-59 months of age with severe malnutrition * child admitted to hospital because of severe malnutritionwith medical complications as defined by the current world health organization guidelines or has no appetite if there are no complications * primary caregiver (self-identified) present at hospital. exclusion criteria: * primary caregiver declined to give informed consent; * child with a known terminal illness (i.e. in the opinion of the treating physician the child is likely to die within six months) * child requires a surgical procedure.

Keywords: child malnutrition child development counseling
effect of music on pain and anxiety paddle edometrial biopsy

Conditions: Gynecologic Nursing

Summary: this study was conducted as a randomized controlled trial to investigate the effect of music recital on pain and anxiety in women undergoing pipelined endometrial biopsy.

this study was conducted as a randomized controlled trial to investigate the effect of music recital on pain and anxiety in women undergoing pipelined endometrial biopsy. the data were collected in the intervention room of the mixed service of a state hospital in ankara between december 2023 and april 2024. power analysis was performed with the g\*power 3.1 program to determine the number of people to be included in the study. the study was conducted with a total of 64 women, 32 in the control group and 32 in the experimental group. the data were collected using the personal information form, "visual comparison scale" to assess the severity of pain, and "state and trait anxiety scale" to determine the level of anxiety. the experimental group listened to acemashiran maqam music, while the control group received routine care. there was no significant difference between the control and experimental groups in the distribution of socio-demographic characteristics.

Eligibility criteria:
inclusion criteria: * women aged 18 and over who underwent endometrial biopsy for the first time exclusion criteria: those who did not fill out the consent form, those who were illiterate, those who were receiving inpatient treatment during the study, those with psychiatric illness (dementia, psychosis, etc.), those who were on regular medication (such as analgesics, anxiolytics or sedatives), those who had communication problems (vision, hearing and perception problems), women who were in pain before the procedure were not included.

Keywords: pain anxiety